China Transcatheter Aortic Valve Replacement (TAVR) Market Report 2021-2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “China Transcatheter Aortic Valve Replacement (TAVR) Market Insight Report, 2021-2025″ report has been added to ResearchAndMarkets.com’s offering.

In 2019, the global market for heart valves is close to US$ 6 billion, of which TAVR exceeds US$ 4 billion and surgical valves is about US$ 1.8 billion.

We estimate that the total market in China is about RMB 2 billion. Surgical valve is still the basic demand of valve replacement market in China, and domestic biological surgical valve will benefit from the replacement of mechanical valve and imported valve.

At present, the domestic TAVR base is extremely low, which will become the biggest growth point with the continuous listing and academic promotion of products. TMVR technology is still immature, but the patient population is 5~10 times that of TAVR, which is the direction of industry R&D layout.

There are many patients with rheumatic heart disease in history, and the age of first treatment is 30-40 years old, which is far lower than that in Europe and America, resulting in a large amount of mechanical valves used in China. Now, with the accumulation of durability data of surgical bioprosthetic valve and the gradual change of patient population structure in China, this situation is changing.

From the perspective of industry development, there are already many domestic enterprises in the valve field. With the listing of Edward’s interventional valve SAPIEN3 in China in 2020, we believe that China’s valve industry is at the development base, and the market space needs to be opened urgently.

According to the characteristics of the valve industry in China, we believe that the domestic valve industry may have the following development trends:

• Biological valves will gradually replace mechanical valves;
• Domestic bioprosthetic valve has a large import substitution space;
• Interventional surgery and surgery will complement each other for a long time, which is mainly determined by clinical needs. At present, interventional surgery can only treat patients with aortic valve diseases, with a larger proportion of patients with mitral and tricuspid valves. There is no mature interventional replacement scheme in the world. Therefore, it is expected that interventional surgery and surgery will complement each other for a long time to come.
• In the way of interventional operation, we think that spherical expansion valve may have more advantages than self-expansion valve. Spherical expansion valve has greater radial support and shorter structure, lower clinical risk and better effect, and may have more advantages in clinical use.
• In the long run, valve durability is still the core. We believe that the key to measure a valve is not whether it can be used, but whether it can be used more durably, whether it is an interventional valve or a surgical valve. Because the heart is the most complex organ of human body, it is difficult to change the valve frequently, so whether the valve can be used for a long time is the most important factor to measure whether a valve is a good product. Edward fully proved the durability of his valve through his unique anti-calcification technology and long-term large-scale return visit data, and gradually became the leader of the global valve industry.

Key Topics Covered:

1 General Overview

2 Overview of the market of artificial heart valve industry in China

2.1 definition and classification of artificial heart valve

2.2 the development process of China’s artificial heart valve industry

2.3 market size of artificial heart valve industry in China

2.4 China’s artificial heart valve industry chain analysis

2.4.1 upstream analysis

2.4.2 downstream analysis

3 analysis of driving factors of artificial heart valve industry in China

3.1 Population aging drives demand growth

3.2 Biomedical materials help industry development

3.3 New technology reduces the difficulty of implantation

4 Analysis of restrictive factors of artificial heart valve industry in China

4.1 Price control risks affect industry profits

4.2 High surgical risk hinders the improvement of surgical permeability

4.3 High-durability products impact the Chinese product market

5. Policy analysis of China’s artificial heart valve industry

6 Analysis of the development trend of artificial heart valve industry in China

6.1 Biological valve and interventional technology are important trends in the development of the industry

6.2 Develop independent intellectual property rights

7 Analysis on the competitive pattern of artificial heart valve industry in China

Companies Mentioned

• Venus Medtech
• Peijia Medical
• MicroPort CardioFlow Medtech Corporation
• Suzhou Jiecheng Medical Technology Co., Ltd.
• Beijing Balance Medical Technology Co.,Ltd

For more information about this report visit https://www.researchandmarkets.com/r/943jne

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900